Clinical Trials Browser

INDUSTRY × Lymphoma, Follicular × fludarabine × Clear all

Lymphoma, Lymphoma, Follicular, Recurrence

NCT05826535 2026-02-24

Study of LYL314 in Aggressive Large B-Cell Lymphoma

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT03105336 2025-12-23

ZUMA-5

Phase 2 Completed

159 enrolled 27 charts 1 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06285422 2025-11-28

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

Phase 1 Active not recruiting

6 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04245839 2025-11-05

TRANSCEND FL

Phase 2 Active not recruiting

276 enrolled 2 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05371093 2025-10-15

ZUMA-22

Phase 3 Active not recruiting

231 enrolled

Lymphoid

Lymphoma, Follicular

NCT04735471 2025-06-18

GLEAN-1

Phase 1 Terminated

34 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05665062 2025-04-06

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Phase 1 Active not recruiting

36 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04323657 2023-03-16

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1/2 Completed

6 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00562965 2018-01-09

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Phase 3 Terminated

29 enrolled 14 charts

Lymphoid

Lymphoma, Follicular

NCT00060684 2015-01-19

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Phase 1 Completed

30 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

ALPHA

Study of LYL314 in Aggressive Large B-Cell Lymphoma

ZUMA-5

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

TRANSCEND FL

ZUMA-22

GLEAN-1

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma